O-GlcNac Modified Proteomics Study of the Maturation of Hemodialysis Arteriovenous

Study Overview
=================
Brief Summary
-----------------
We divided into three parts to carry out. Firstly, evidence the pre-existing fibrosis in vein of AVF failure patients. investigation of expression, the role, and the mechanism by which the identified O-GlcNAac proteins promote, maturation of AV fistula. Finally, ddress and compare the proteomics differentiation between failure and maturation of AVF patients.

Detailed Description
-----------------
End stage renal disease (ESRD) patients requires hemodialysis to maintain bloodstream functions. Before the hemodialysis, the patients requires a long-term vascular access, which best choice is Arteriovenous fistulas (AVF). However, 1/3 of patients were failure in AVF maturation, and it is still unknown. Our preliminary data have shown that pre-exisiting fibrosis in vein of AVF failure. Here, we will investigate whether pre-existing fibrosis of vein is asssociated with circulating fibrocytes in AVF failure, and further to address molecular mechanism of fibrocytes differentiation. We will divide into three parts to carry out. Firstly, evidence the pre-existing fibrosis in vein of AVF failure patients. Secondary, investigation of expression, the role, and the mechanism by which the identified O-GlcNAac proteins promote, maturation of AV fistula. Finally, address and compare the proteomics differentiation between failure and maturation of AVF patients. We hope that through this project, we can obtain signifiture molecules for precision detection and solve the current clinical unmet need.

Official Title
-----------------
O-GlcNac Modified Proteomics Study of the Maturation of Hemodialysis Arteriovenous

Conditions
-----------------
Arteriovenous Fistula Occlusion

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age of 20 and older adult patients, and preoperatively clinical and ultrasound assessment of the arm vessels are fisible for the creation of a native HDAVF that include:the augmented diameters of the veins is > 2.0 mm and the diameter of the radial artery is> 2.0 mm. Besides, there is no obvious stenosis of vessels in the forearm. Exclusion Criteria: The patient refused to join the study Too weak Serious heart failure Unconsciousness Bedridden for long time systemic lupus erythematosus(SLE), or other known autoimmune diseases The physician excludes the possibility of creating a wrist HDAVF before surgery Surgeon preoperatively identifies vessel inadequacy for the creation of a wrist HDAVF Choose a site other than the wrist for surgery Unexpected negative complications happen during surgery that prevent the completion of a wirst HDAVF

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Matured<br>It is defined as the target HDAVF can be used | Other: No intervention<br>* No intervention<br>|
| Non-matured<br>RC-AVF underwent additional intervention after 90 days of observation | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The diameter of each passage of the passage vein (forearm head vein) of the arterial and venous access within three months | Comparison of the various methods to achieve within three months the checkpoint path diameter increase rate (two time points measurement difference). | Postoperative Three months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arteriovenous Fistula, vascular smooth muscle, histological technique, O-GlcNac, proteomics